Vor Biopharma (VOR) EBT (2020 - 2026)
Vor Biopharma (VOR) posted quarterly EBT of -$31.3 million for Q1 2026, up 8.31% year-over-year from -$28.9 million in Q1 2025, and up 5.83% quarter-over-quarter from -$33.3 million in Q4 2025.
Vor Biopharma (VOR) EBT (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported EBT for 7 consecutive years, with -$31.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 8.31% year-over-year to -$31.3 million; the TTM figure through Mar 2026 stood at -$375.0 million (down 203.16% YoY), while the FY2025 annual figure was -$598.5 million, down 133.68% from the prior year.
- EBT rose to -$31.3 million in Q1 2026 per VOR's latest filing, from -$33.3 million in the prior quarter.
- Across five years, EBT topped out at -$23.0 million in Q2 2022 and bottomed at -$283.9 million in Q2 2025.
- Historically, EBT has averaged -$44.2 million across 5 years, with a median of -$30.0 million in 2023.
- Annual changes were most pronounced in 2022 — EBT soared 89.35% — and 2025, when it sank 917.39%.
- Vor Biopharma's EBT stood at -$26.6 million in 2022, then decreased by 7.62% to -$28.7 million in 2023, then slipped by 13.05% to -$32.4 million in 2024, then decreased by 2.71% to -$33.3 million in 2025, then increased by 5.83% to -$31.3 million in 2026.
- Business Quant data shows VOR's EBT at -$31.3 million in Q1 2026, -$33.3 million in Q4 2025, and -$26.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -44.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.43 Mn |
| Mar 31, 2026 | -31.34 Mn |
| Dec 31, 2025 | -33.28 Mn |
| Sep 30, 2025 | -26.41 Mn |
| Jun 30, 2025 | -283.94 Mn |
| Mar 31, 2025 | -34.17 Mn |
| Dec 31, 2024 | -32.40 Mn |
| Sep 30, 2024 | -29.21 Mn |
| Jun 30, 2024 | -27.91 Mn |
| Mar 31, 2024 | -32.44 Mn |
| Dec 31, 2023 | -28.66 Mn |
| Sep 30, 2023 | -33.47 Mn |
| Jun 30, 2023 | -30.43 Mn |
| Mar 31, 2023 | -29.98 Mn |
| Dec 31, 2022 | -26.63 Mn |
| Sep 30, 2022 | -24.97 Mn |
| Jun 30, 2022 | -22.99 Mn |
| Mar 31, 2022 | -23.46 Mn |
| Dec 31, 2021 | -18.97 Mn |
| Sep 30, 2021 | -19.25 Mn |